Gomesin is an 18-residue cysteine-rich antimicrobial peptide produced by hemocytes of the spider Acanthoscurria gomesiana. In the present study, the antifungal properties of gomesin against Cryptococcus neoformans, the etiologic agent of cryptococcosis, were evaluated. Gomesin bound to the cell surface of cryptococci, which resulted in cell death associated with membrane permeabilization. Antifungal concentrations of gomesin were not toxic for human brain cells. Supplementation of cryptococcal cultures with the peptide (1 mM) caused a decrease in capsule expression and rendered fungal cells more susceptible to killing by human brain phagocytes. The possible use of gomesin in combination with fluconazole, a standard antifungal drug, was also evaluated. In association with fluconazole, gomesin concentrations with low antimicrobial activity (0.1-1 mM) inhibited fungal growth and enhanced the antimicrobial activity of brain phagocytes. These results reveal the potential of gomesin to promote inhibition of cryptococcal growth directly or by enhancing the effectiveness of host defenses.
Introduction
Cryptococcus neoformans is an encapsulated yeast-like pathogen that causes meningoencephalitis in immunosuppressed individuals. Cryptococcal meningitis is one of the most common fungal infections developed by HIV-1 infected patients and is the third most frequent neurological complication in patients with AIDS (Del Valle & Piña-Oviedo, 2006) . Options for the treatment of cryptococcal meningitis include amphotericin B during the first weeks, followed by fluconazole treatment until immune reconstitution (Bicanic & Harrison, 2004) . The use of amphotericin B and fluconazole, however, can be accompanied by several undesired side effects, including toxicity for the host and fungal drug resistance (Dan & Levitz, 2006) . In this context, it is clear that new alternatives for the treatment of cryptococcosis are required.
Antimicrobial peptides (AMPs) represent an abundant and diverse group of molecules that are produced by many tissues and cell types in a variety of microbial, plant and animal species (Brogden, 2005; Yount et al., 2006) . Their general properties such as amphipathicity and cationicity allow them to form pores in biological membranes, resulting in microbial death. AMPs also exert their antimicrobial activity by inhibiting cell-wall assembly, nucleic-acid and protein synthesis (Brogden, 2005) , indicating that specific target molecules can be involved in these activities. Besides the direct action on microorganisms, AMPs can act as immune modulators (Brown & Hancock, 2006; Yount et al., 2006) .
Gomesin is a small-sized AMP produced and stored in hemocytes of the mygalomorph spider Acanthoscurria gomesiana (Silva et al., 2000; Lorenzini et al., 2003) . The peptide, which contains 18 amino acids and two disulfide bridges, adopts a b-hairpin-like structure, as determined by 2-D nuclear magnetic resonance and molecular dynamics studies (Mandard et al., 2002) . Gomesin presents potent antimicrobial activity against Gram-positive and -negative bacteria, protozoa and fungi (Silva et al., 2000 , Moreira et al. 2007 . The putative mechanism involved in the antimicrobial action of gomesin includes membrane permeabilization (Mandard et al., 2002 , Fazio et al, 2006b , although the involvement of other targets had not been investigated.
The anticryptococcal effects of gomesin were evaluated in the present work. It is demonstrated that gomesin is a potent anticryptococcal agent that, alone or in combination with fluconazole, can interfere with C. neoformans growth and interaction with host cells.
Materials and methods

Microorganisms
Cryptococcus neoformans strains T 1 -444 and HEC3393 (serotype A, clinical isolates) are, respectively, largely and poorly encapsulated isolates, as previously characterized (Rodrigues et al., 1997; Barbosa et al., 2006) . Strain Cap67 is a wellcharacterized acapsular mutant of C. neoformans extensively used in previous studies. Cryptococcus neoformans was cultivated with shaking for 48 h, at 25 1C, in a chemically defined medium (Rosas et al., 2001) . Cell suspensions were quantified by counting the number of yeasts in a Neubauer chamber.
Gomesin synthesis
Gomesin was manually synthesized on 4-methylbenzhydrylamine resin using the t-Boc strategy as described previously (Fazio et al., 2006a) .
Binding of gomesin to the surface of C. neoformans A rabbit antibody to gomesin (Lorenzini et al., 2003) was used as a probe in the analysis of cellular sites for the peptide in cryptococci. In these analyses, acapsular yeast were used since, although capsule expression seems not to regulate cryptococcal sensitivity to gomesin (Fig. 1 ), it has been described in the literature that the capsular polysaccharide negatively modulates the interaction of antibodies with the cell surface of C. neoformans (Rodrigues et al., 2000) . Yeast cells (10 6 ) were suspended in 100 mL of a 1 mM gomesin solution and incubated for 5 min at 37 1C. This concentration was chosen based on the results described in Fig. 1 , as detailed in Results. The cell suspension was washed in phosphate-buffered saline (PBS) and then fixed in 4% paraformaldehyde. Yeast cells were then blocked and washed as described previously (Rodrigues et al., 2000) and incubated with the rabbit antigomesin antibody (10 mg mL À1 ) for 1 h at room temperature, followed by incubation with a rhodamine-labeled goat antirabbit IgG (Fc specific) antibody (Sigma). Yeast cells were finally observed with an Axioplan 2 (Zeiss, Germany) fluorescence microscope. Images were acquired using a Color View SX digital camera and processed with the software system ANALYSIS (Soft Image System). Control preparations were developed as described above, except for the incubation with gomesin.
Antifungal effects of gomesin and fluconazole
Cryptococcus neoformans cells (strains HEC3393, T 1 -444 and Cap67; 2 Â 10 5 mL À1 ) were treated with the peptide in concentrations varying from 0.5 to 10 mM (in PBS) for 5 min. Control systems were treated with PBS alone. Cell suspensions were then washed with sterile PBS and plated onto Sabouraud dextrose agar (SDA) plates for CFU counting. In some experiments, the anticryptococcal effects of fluconazole, alone or in combination with gomesin, were also evaluated, following the same protocol. All experiments were performed in triplicate sets and statistically analyzed using Student's t-test.
Permeabilization of cryptococci after treatment with gomesin
Membrane permeabilization was evaluated using the method described by Mangoni et al. (2004) , with minor modifications. The fluorochromes used were the double-stranded DNA-binding dye 4',6-diamidino-2-phenylindole (DAPI), to stain all fungal cells independently on viability and the green fluorescent probe fluorescein isothiocyanate (FITC), which is unable to traverse the cytoplasmic membrane of cells unless permeabilized. Based on this property, the percentage of permeabilization in a cryptococcal population was considered as the number of FITC-stained cells per 100 yeasts. Yeast cells (10 6 ) were suspended in 50 mL of a 2 mM gomesin solution for 5 min and further washed with PBS. This concentration was chosen based on the results described in Fig. 1 , as detailed in 'Results'. Yeasts were then suspended in 50 mL of a DAPI solution (10 mg mL À1 in PBS).
After 10 min at 30 1C, the DAPI solution was removed and the cells washed again with PBS. An FITC stock solution (10 mg mL À1 in dimethyl sulfoxide) was diluted to 6 mg mL À1 in PBS and used to resuspend the cells, followed by incubation at 30 1C for 30 min. After washing with PBS, yeast cells were transferred to glass slides and observed with an Axioplan 2 (Zeiss, Germany) as described above. Controls were run in the absence of the peptide. Cell viability was determined by CFU counting after peptide treatment, producing results essentially similar to those described in Fig. 2 .
Effects of gomesin on capsule expression
To evaluate whether gomesin affects capsule expression in C. neoformans, 10 4 cells of the largely encapsulated strain T 1 -444 were suspended in 100 mL of minimal media supplemented with 1 mM gomesin and cultivated for 48 h in 96-well plates. This concentration was chosen based on the results described in Fig. 1 , as detailed in 'Results'. Control preparations were identical, except for the presence of gomesin. Yeast cells were collected and washed by centrifugation for further determinations of capsule expression. Capsule sizes, defined as the distances between the cell wall and the outer border of the capsule in India ink-stained yeast cells, were determined using IMAGEJ software (version 1.33), elaborated and provided by National Institutes of Health (NIH, http://rsb.info.nih.gov/ij/). Cell diameters were determined using the same software. Final measurements were presented as a ratio of capsule size/cell diameter. The ability of gomesin to regulate capsule synthesis and/or secretion was evaluated by cultivation of cryptococci in the presence of 1 mM gomesin. In this assay, C. neoformans cells that were cultivated in the presence of gomesin as described above were stained with Trypan blue and the number of viable (nonstained) yeast determined. The number of viable cryptococci (control cells or yeast obtained from gomesincontaining cultures) was then normalized to 10 4 and cells were again cultivated in the absence (control) or in the presence of 1 mM gomesin as described above. In 24 h intervals, 10 mL of the culture suspension was taken for CFU determination. The concentration of glucuronoxylomannan (GXM), the major capsular polysaccharide of C. neoformans, in the culture supernatants was determined in the same intervals, using capture ELISA as described previously (Casadevall et al., 1992) .
Yeast killing by human brain cells
Human brain phagocytes (U-87 MG, glioblastoma cells) were used in this study based on previous reports demonstrating the relevance of their interaction with C. neoformans (Lee et al., 1994) . They were provided by Dr Dumith Chequer Bou-Habib (Fiocruz, Rio de Janeiro, Brazil) and cultured in Dulbecco' modified Eagle's medium (Gibco-BRL, Gaithersburg, MD) supplemented with 2 mM L-glutamine and 10% complement-inactivated fetal bovine serum (FBS) (Gibco-BRL, Gaithersburg, MD). Viable fungal cells obtained from gomesin (1 mM)-containing cultures were washed in PBS and allowed to interact with brain phagocytes at a fungi : host cell ratio of 10 : 1 during 4 h at 37 1C. Nonassociated fungi were then removed by washing and host cells were lysed with sterile cold water. The resulting suspension was plated onto SDA plates. After 48 h the number of CFU was determined. In some cases, after a 4 h incubation of C. neoformans with human cells, nonassociated fungi were removed by washing. Gomesin (0.1 mM) and/or fluconazole (1 mM) were diluted in fresh media and added to the systems. In this model, the cells were maintained at 37 1C for 24 h in the presence of the antifungal compounds and then lysed as described above for CFU counting. All experiments were performed in triplicate sets and statistically analyzed using Student's t-test.
Analysis of host cell damage by the lactate dehydrogenase (LDH) assay
To evaluate host cell injury induced by gomesin, human brain cells (U-87 MG) (10 5 ) were incubated with the peptide (0.1-10 mM, 100 mL) in fresh medium for periods of 24 h. Supernatants were then collected, centrifuged for removal of debris and assayed for the presence of released LDH as described previously (Barbosa et al., 2006) . Alternatively, human cells were incubated with the standard drug fluconazole (0.1-10 mM) in the same conditions as described above. Positive and negative controls consisted, respectively, of a U-87 MG Triton X-100 (10%) lysate and supernatants of nontreated human cells after 18 h of cultivation. All experiments were performed in triplicate sets and statistically analyzed using Student's t-test.
Results
Antifungal properties of gomesin
Treatment of different C. neoformans isolates with gomesin for 5 min resulted in a dose-dependent profile of fungal killing (Fig. 1) . There was no evident correlation between capsule expression and susceptibility to gomesin. The peptide apparently uses the cell surface as a major binding site in C. neoformans, as inferred from the reactivity of gomesin with the cell wall of acapsular cells after 5 min incubation (Fig. 1, inset) . Identical results were observed when gomesin was incubated with C. neoformans for 12 h (data not shown), suggesting that the peptide is not internalized.
The ability of gomesin to induce permeabilization in C. neoformans cells was evaluated by a fluorescence-based method. Levels of fungal killing after treatment of cryptococci with the peptide concentrations of 2, 5 and 10 mM were similar (Fig. 1) ; hence the 2 mM concentration was selected as the lowest gomesin dose presenting effective fungicidal effects. After treatment of C. neoformans (strain HEC3393) with PBS (control) or the peptide for 5 min, cryptococci were sequentially stained with DAPI and FITC. Analysis of these cells by fluorescence microscopy ( Fig. 2) revealed nuclear staining of both control and peptide-treated yeasts after incubation with DAPI. FITC staining, however, was only observed in the cytoplasmic compartments of peptidetreated yeasts, indicating that gomesin causes permeabilization in C. neoformans. The percentage of permeabilized cells corresponded to 79%, which is in full agreement with the results demonstrated in Fig. 1 . Both encapsulated cells and acapsular mutants were evaluated, producing similar patterns of fluorescence after gomesin treatment (data not shown).
Gomesin-treated cryptococci present an impaired ability to express capsular polysaccharides and reduced resistance against brain phagocytes
The suggestion that gomesin interacts with the cryptococcal cell surface (Fig. 1 ) led to the evaluation on whether cultivation of C. neoformans in the presence of gomesin also affects capsule expression. Based on the results presented in Fig. 1 , the concentration of 1 mM was chosen, since it was the higher gomesin concentration at which inhibitory effects were relatively low. Cryptococcus neoformans cultivated in the presence of gomesin exhibited an average increase in cell diameter (not including capsule size) of around 38%, compared with control cells (P 4 0.05). Cells obtained from the gomesin-containing medium were significantly less effective than control cells (P o 0.0001) in their ability to express capsular polysaccharides (Fig. 3a) as concluded from the increased ratio of capsule size per cell diameter. Microscopic observations revealed that virtually all cells had smaller capsules, although the level of capsule inhibition varied considerably in the cryptococcal population. Defective capsule expression or assembly was apparently related to an impaired ability of synthesis and/or secretion of GXM, since the concentration of soluble polysaccharide in culture fluids was significantly smaller (P o 0.01) in the presence of the peptide (Fig. 3b) . This effect was apparently not related to smaller cell number in the culture or other metabolic faults, since the growth rates of control or peptide-treated cryptococci were very similar. The fact that viable cells proliferated normally in the presence of gomesin may indicate that gomesin-resistant yeasts could be selected after cultivation in the presence of the peptide, although it has not been experimentally proved.
The susceptibility of gomesin-treated cells to the antimicrobial action of brain phagocytes was also evaluated. The results shown in Fig. 3c demonstrate that peptide-treated cells are significantly more susceptible to killing by human phagocytes than control yeasts (P o 0.0001). The recovery of viable yeasts when gomesin-treated cells were used in phagocytosis assays represented only 5% of the values obtained after incubation of control yeasts with phagocytes. The enhanced susceptibility to macrophages was apparently not related to the antimicrobial effects of gomesin alone, since the indices of fungal killing by the 1 mM dose of the peptide were considerably lower than those observed after incubation with macrophages (for comparison, Figs 1, 3 and 4) .
Synergistic effects of gomesin and fluconazole
The possible use of gomesin at concentrations below the range of effective antimicrobial activity in combination with the standard drug fluconazole to kill cryptococci was also evaluated. Dose-response curves of the anticryptococcal activity of fluconazole (data not shown) indicated that, in the presence of 1 mM fluconazole, only partial fungal killing (25%) was obtained under the conditions used in this study. At the same concentration, similar levels of antifungal activity were obtained for gomesin (Fig. 4) . When both antimicrobial components were combined, however, fungal killing was close to 90%. These results indicate that gomesin and fluconazole act synergistically to kill C. neoformans. Therefore, it was tested whether gomesin and fluconazole could produce similar results in infected phagocytes.
The toxicity of gomesin and fluconazole to human brain phagocytes by the release of LDH, a classical marker of cell injury, was evaluated. Figure 5a shows the LDH activity of U-87 MG cells treated with each drug. Gomesin and fluconazole were significantly toxic only at 10 mM, using positive (Triton lysate) and negative (no treatment) controls as references. A partially inhibitory dose of fluconazole (1 mM) and the lowest dose of gomesin (0.1 mM) were then selected for further experiments. Fluconazole (1 mM) and gomesin (0.1 mM) were combined and their concomitant ability to cause injury in brain cells was tested. LDH activity from these culture supernatants was similar to that found in culture fluids on untreated cells, suggesting that, at low concentrations, a combination of fluconazole and gomesin is not toxic to brain cells. The results presented in Fig. 5b demonstrate that brain phagocytes, in the presence of fluconazole and gomesin alone, produced only partial inhibitory activity, as concluded from the comparison of CFU counts from control or drug/peptide-treated phagocytes. In the presence of a combination of both antimicrobial compounds, however, an impressive increase in antifungal activity was observed.
Discussion
Gomesin was the first peptide isolated from spider exhibiting antimicrobial activities (Silva et al., 2000) , including several pathogens. The mechanisms by which gomesin exert its antimicrobial effects are not well known but, since the peptide is cationic and present both hydrophobic and hydrophilic domains, plasma membrane insertion followed by its permeabilization might be at least one of its action mechanism, as discussed previously (Mandard et al., 2002 , Fazio et al., 2006b ). Gomesin does not act via a stereospecific receptor for several bacterial and fungal strains as demonstrated by Silva et al., 2000 . The anticryptococcal activity of gomesin was previously suggested (Silva et al., 2000) , but key information such as cellular targets, toxicity for brain cells, effects on capsule expression and host susceptibility were not explored. Due to the antimicrobial potential of the peptide and clear problems with cryptococcosis treatment, the current study aimed at the evaluation of the anticryptococcal activity of gomesin. Data from this study indicate that a short period of incubation of different C. neoformans strains with the peptide results in fungal death. The cryptococcal sensitivity to gomesin is apparently not related to capsule expression, since isolates differently expressing capsular polysaccharides and an acapsular mutant were similarly affected by the peptide. The ability of gomesin to cross the capsular barrier and kill cryptococci is of potential relevance, since C. neoformans can express very large capsules during infection (Rodrigues et al., 1999) .
Gomesin also affects capsule expression in C. neoformans. A reduced capsule was associated with a decreased concentration of soluble GXM, which is regularly secreted in culture supernatants and used for distal capsule growth (Zaragoza et al., 2006) . GXM is also the major capsular polysaccharide and virulence factor of C. neoformans (Rodrigues et al., 1999; Vecchiarelli, 2000; Perfect & Casadevall, 2002) . Gomesin-treated cells had an increased diameter, as described for C. neoformans cells with defective mechanisms of GXM secretion (García-Rivera et al., 2004) . The mechanisms by which gomesin could inhibit capsule secretion and/or expression are still unclear but, since gomesin is apparently not internalized by cryptococci, it can be speculated that low concentrations of the peptide (1 mM) could affect signaling pathways related to capsule expression. In higher concentrations, cell death pathways could be activated. It is also demonstrated that yeast cells treated with gomesin were more efficiently killed by brain cells than by control yeast. In this context, this study indicates that the peptide could act in the control of cryptococcosis by killing C. neoformans and also by down modulating the expression of its major virulence factor.
Low doses of fluconazole and gomesin alone presented no antimicrobial activity but, in combination, a strong inhibition of fungal growth was observed, with no damage to human cells. The mechanisms by which gomesin and fluconazole could act synergistically are still unknown. It can be speculated that, since gomesin can induce cell permeabilization in C. neoformans, the amount of fluconazole necessary to effectively reach the fungal cytoplasm and inhibit ergosterol synthesis could be decreased in the presence of the peptide. Combination antifungal therapy is in fact an alternative for the treatment of cryptococcosis. For instance, recent clinical data confirm that amphotericin B, which also induces membrane permeabilization, and the inhibitor of DNA synthesis flucytosine represent the most active combination for patients with cryptococcal meningitis although they both present significant toxicity (Baddley & Pappas, 2005) . It has been recently suggested that C. neoformans is a facultative intracellular pathogen (Feldmesser et al., 2001; Tucker & Casadevall, 2002) . It is therefore believed that the intracellular environment works as a protective niche for C. neoformans during infection, avoiding interference of the host immune response and drug-mediated killing. In our model, combined low doses of fluconazole and gomesin resulted in enhanced indices of killing of C. neoformans by brain phagocytes. Supposedly, gomesin could enhance the permeability of host cells, allowing fluconazole to reach the intracellular environment and inhibit fungal growth. In this context, it has been described that several cationic and amphipathic peptides have the potential to be used as effective enhancers of the intracellular delivery of macromolecules (Kueltzo & Middaugh, 2003) , genes (Kichler et al., 2006) and drugs (Trehin & Merkle, 2004) . In the presence of gomesin, therefore, conventional antifungal therapeutics could be used in smaller and, consequently, less-toxic concentrations. Another possibility is that, even in lower doses of gomesin (0.1 mM), capsule expression in C. neoformans could be affected, rendering fungal cells more susceptible to the antimicrobial action of macrophages.
The current data indicate that gomesin, individually or in combination with fluconazole, could be of considerable application as a new anticryptococcal agent. In this regard, the potential to control cryptococcosis in animal models are the focus of future studies. In addition, the mechanisms by which the peptide binds to the cell surface of cryptococci inducing permeabilization and killing remain not understood. Purification of putative gomesin-binding molecules from C. neoformans cells followed by structural elucidation will represent crucial analyses on this subject.
